Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Aug 3, 2010

Premium

Affymetrix this week released version 1.1 of its ChAS Chromsome Analysis Suite software,

The the new software includes improved allele peaks algorithm and loss of heterozygosity detection algorithm. Additionally, the minimum and default values of the median-smooth-marker-count algorithm have been changed.


Zoiray Technologies recently launched its Spectral Reflectance Imaging Biosensor system, a multiplexed immunoassay platform for life science research and clinical diagnostics. The SRIB supports array-based immunoassays that identify the presence of specific protein biomarkers in blood, urine, or saliva, according to the Boston-based firm.

Designed by Wellesley, Mass.-based Bodkin Design and Engineering, the SRIB incorporates a class IIIb tunable laser, high-resolution camera, fluidics, and digital control. It automatically carries out specimen delivery, reagent introduction, optical interrogation, specimen disposal, and data analysis, the firm said.

During its operation, a biochip containing active proteins is loaded into the device. The specimen and reagents are then delivered to the reaction flow cell, where incubation takes place. The sample is optically probed with the laser and evaluated. Zoiray said that key applications of the SRIB include biomedical research, disease pathogen identification, and homeland security.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.